What we do?
We develop an innovative human erythropoietin-based neurotherapeutic to meet the needs of millions of people around the world who suffer from central nervous systems conditions like Parkinson´s disease, Alzheimer´s disease, multiple sclerosis, stroke, among others; for which, nowadays there is no effective treatment.
How we do it?
Human erythropoietin (hEPO) is a widely used biotherapeutic for anemia treatment because it stimulates red blood cells production. Besides, hEPO has neuroprotective and neuroplastic activity. Nevertheless, when it is used as a neuropharmaceutical in patients who do not suffer from anemia, it causes erythropoietic activity-associated side effects. Thus, from BioSynaptica, we have developed hEPO-based neurotherapeutic candidates through an innovative idea, to block its undesired effect but preserving its neurotherapeutic potentiality.
Development of new hEPO variants through glycoengineering
In vitro and in vivo confirmation of their blocked erythropoietic activity
Confirmation of their potentiality to promote neuroplastic/neuroprotective action on neuron-derived primary cultures
Validation for their long-lasting circulation in blood
National phase patent request (after positive evaluation of patentability by PCT) in Europe, EEUU, and twelve other countries which represent the most promising markets
Evaluation of their in vivo capacity to cross the blood-brain barrier and their neuroplasticity (proof-of-concept in wild type animals)
To develop and to scale up the production process of the hEPO-variants
To confirm theirneuroprotective/neuroplastic actions in animal models of humanneurological disorders
To begin pre-clinical trials
WHO WE ARE?
Milagros Bürgi, PhD
Marcos Oggero-Eberhardt, PhD
Ricardo Kratje, PhD
Matías Depetris, PhD
Director & Co-Founder
Dra. Milagros Bürgi
Dr. Ricardo Kratje
Dr. Marcos Oggero-Eberhardt
Dr. Matías Depetris